Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

PURPOSE: Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. METHODS: Patients with advanced solid m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Abou-Alfa, Ghassan K., Lewis, Lionel D., LoRusso, Patricia, Maitland, Michael, Chandra, Priya, Cheeti, Sravanthi, Colburn, Dawn, Williams, Sarah, Simmons, Brian, Graham, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520972/
https://ncbi.nlm.nih.gov/pubmed/28523596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3315-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados